News & Updates
Filter by Specialty:
Infliximab trumps other biologics as maintenance drug in CD
Among the many biologics used to treat adults with moderate-to-severe Crohn’s disease (CD), infliximab subcutaneous (SC) 120 mg every 2 weeks (Q2W) demonstrates the highest efficacy in clinical remission during maintenance treatment of 52 to 64 weeks’ duration, according to the results of a recent study presented at CCC 2025.
Infliximab trumps other biologics as maintenance drug in CD
19 Feb 2025
Oral, gut flora mainstay tied to stroke risk
A study presented at ISC 2025 shows elevated levels of Streptococcus (S.) anginosus – a type of bacteria present in the normal oral and gastrointestinal microflora – in the mouth and gut of recent stroke survivors in Japan.
Oral, gut flora mainstay tied to stroke risk
19 Feb 2025
OLE reflects long-term efficacy, safety of mirikizumab for CD
Initial findings from the ongoing VIVID-2 open-label extension (OLE) study comprising week 52 endoscopic responders from the phase III VIVID-1 trial demonstrate the long-term clinical and endoscopic efficacy of the selective anti-interleukin-23p19 monoclonal antibody mirikizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).
OLE reflects long-term efficacy, safety of mirikizumab for CD
18 Feb 2025
SC dose escalation restores efficacy of infliximab in IBD patients
Escalating the dose of subcutaneous (SC) CT-P13, a biosimilar of infliximab, from 120 to 240 mg every 2 weeks appears to bring back the efficacy of the drug in patients with inflammatory bowel disease (IBD) who no longer respond to treatment, suggests a study presented at 2025 Crohn's & Colitis Congress.
